EpiCept possesses a unique business model that sets it apart from typical specialty pharmaceutical and biotech companies and presents a unique value proposition to investors.

EpiCept has a balanced pipeline of early- to late-stage product candidates which allows the Company to pursue large market opportunities in a focused, efficient way that minimizes dependence on any one product opportunity.

In pursuing promising oncology product candidates, the Company utilizes its expertise in the identification of promising candidates and it's ability to design and manage complex trials.

In developing analgesic product candidates, EpiCept utilizes several proprietary formulations and topical delivery technologies to administer FDA-approved analgesics to patients. The utilization of these FDA-approved drugs is expected to reduce the risks associated with new drug development, lower development costs and speed time to market for product candidates.

EpiCept plans to market products for which it obtains regulatory approval through its own sales force in the U.S. whenever it is consistent with the market potential of the candidate drug. If the market opportunity requires a larger sales force, the Company will pursue co-marketing, co-promotion, licensing and distribution arrangements with third-party collaborators. The Company retains maximum flexibility to select the marketing method that will optimize market penetration and commercial acceptance of its products.